ストックスクリーナーアプリを入手
0.00
100.00%
-4.66
前日終値:
$4.66
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$1.05B
収益：
$81.04M
当期純損益:
$161.96M
株価収益率:
0.00
EPS:
0.7146
ネットキャッシュフロー:
$-144.00M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
0.00 | 1.05B | 81.04M | 161.96M | -144.00M | 0.7146 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-25 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 開始されました | SVB Securities | Outperform |
| 2023-01-19 | アップグレード | UBS | Neutral → Buy |
| 2023-01-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-01-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Hold |
| 2021-06-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-04-26 | 再開されました | Credit Suisse | Underperform |
| 2021-04-26 | 開始されました | Guggenheim | Neutral |
| 2020-12-10 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 開始されました | BofA Securities | Buy |
| 2020-09-08 | 開始されました | Credit Suisse | Neutral |
| 2020-09-08 | 開始されました | Jefferies | Hold |
すべてを表示
Curevac N V (CVAC) 最新ニュース
CureVac NV Stock: Biotech Innovator Focused on mRNA Technology and Oncology Pipeline for Long-Term I - AD HOC NEWS
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode - MSN
Market Wrap: Is CureVac NV likely to announce a buybackWatch List & Capital Efficiency Focused Strategies - baoquankhu1.vn
Magnetar Financial LLC Takes $3.53 Million Position in CureVac N.V. $CVAC - MarketBeat
Earnings Miss: Is CureVac NV stock a buy or sellMarket Growth Report & Daily Profit Focused Stock Screening - baoquankhu1.vn
CureVac to initiate Phase 1 trial for its lung cancer therapy - MSN
CureVac (CVAC) Acquisition by BioNTech (BNTX): Your Portfolio Update - Gotrade
CVAC SEC FilingsCurevac B.V. 10-K, 10-Q, 8-K Forms - Stock Titan
Immunic, Inc.Common Stock (NQ: IMUX - The Chronicle-Journal
CureVac N.V. (CVAC) Investor Outlook: Analyzing the Biotech’s Future Amid Major Acquisition - DirectorsTalk Interviews
Aug Action: What is CureVac NVs TAM Total Addressable MarketJuly 2025 WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
BioNTech sets March 10 webcast for 2025 results update - Stock Titan
CEO Moves: Is CureVac N.V. stock a good dividend stockTreasury Yields & Daily Entry Point Trade Alerts - mfd.ru
CureVac N.V. (CVAC) Stock Analysis: Navigating A Transformational Path In Biotechnology - DirectorsTalk Interviews
CureVac (CVAC) Valuation Check After Phase 1 Brain Cancer Vaccine Milestone - Sahm
CureVac’s CVGBM Brain Cancer Vaccine Trial Reaches Completion: What It Means for CVAC Investors - TipRanks
Should you avoid CureVac N.V. stock right nowMarket Movement Recap & Fast Gaining Stock Reports - mfd.ru
New York Life Investment Management LLC Acquires Shares of 258,116 CureVac N.V. $CVAC - MarketBeat
Is CureVac N.V. stock trading near support levelsPortfolio Update Report & Community Driven Trade Alerts - mfd.ru
Is CureVac N.V. stock resilient to inflationMarket Sentiment Report & Technical Entry and Exit Alerts - mfd.ru
Alpine Associates Management Inc. Grows Stock Holdings in CureVac N.V. $CVAC - MarketBeat
CureVac’s Market Exit: A Chapter Closes in the mRNA Race - AD HOC NEWS
CureVac's Public Trading Era Concludes Following BioNTech Acquisition () - aktiencheck.de
CureVac Delisted Following BioNTech Acquisition Completion () - aktiencheck.de
CureVac’s Market Exit: A New Chapter Begins Under BioNTech - AD HOC NEWS
CureVac's Public Market Journey Concludes Following BioNTech Acquisition () - aktiencheck.de
CureVac Shares Cease Trading Following BioNTech Acquisition Finalization - AD HOC NEWS
CureVac Aktie: Vorhersehbare Kursbewegungen - Börse Global
CureVac Aktie: Glänzende Zukunftsperspektiven! - Börse Global
CureVac Concludes Nasdaq Listing Following BioNTech Acquisition - AD HOC NEWS
CureVac Shares Cease Trading Following BioNTech Acquisition - AD HOC NEWS
CureVac Aktie: Strategische Prioritäten - Börse Global
Block Trades: How does SIFY score in quality rankingsInflation Watch & Safe Capital Growth Stock Tips - baoquankhu1.vn
CureVac N.V. (CVAC): Investor Outlook on the German mRNA Innovator Amidst Acquisition by BioNTech - DirectorsTalk Interviews
Aug Wrap: Should you avoid CureVac NV stock right nowJuly 2025 Update & Safe Capital Growth Stock Tips - baoquankhu1.vn
Can CureVac N.V. outperform under higher oil pricesJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - mfd.ru
Toyota and Georg Fischer HR veteran to lead BioNTech's global people strategy - Stock Titan
An Era Ends: CureVac Completes Merger and Delisting Process () - aktiencheck.de
BioNTech Consolidates mRNA Sector with CureVac Acquisition Finalized - AD HOC NEWS
CureVac Concludes Acquisition by BioNTech, Exits Public Markets - AD HOC NEWS
CureVac Shareholders Face Final Tax Reclaim Deadline () - aktiencheck.de
CureVac Exits Public Markets Following BioNTech Acquisition - AD HOC NEWS
BioNTech Completes CureVac Acquisition and Delisting - AD HOC NEWS
CureVac N.V. (CVAC) Investor Outlook: Navigating the Biotechnology Terrain Amidst Strategic Acquisitions - DirectorsTalk Interviews
Earnings Recap: How does XNET score in quality rankingsEarnings Recap Summary & AI Enhanced Trading Signals - baoquankhu1.vn
CureVac (NasdaqGM:CVAC) Valuation After New mRNA Pipeline Progress And Refined Capital Allocation Plan - Yahoo Finance
CureVac’s Market Exit: A New Chapter Under BioNTech’s Banner - AD HOC NEWS
CureVac Shares Cease Trading as BioNTech Acquisition Finalizes - AD HOC NEWS
CureVac’s Independent Journey Concludes with BioNTech Acquisition - AD HOC NEWS
BioNTech’s CureVac Deal Put A Floor Under A Volatile Stock - Finimize
How CureVac N.V. stock reacts to Fed rate cuts2025 Performance Recap & Consistent Growth Equity Picks - Bộ Nội Vụ
Curevac N V (CVAC) 財務データ
収益
当期純利益
現金流量
EPS
1.52%
0.51%
大文字化:
|
ボリューム (24 時間):